Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) closed at $22.42 up 1.68% from its previous closing price of $22.05. In other words, the price has increased by $1.68 from its previous closing price. On the day, 1.15 million shares were traded. CNTA stock price reached its highest trading level at $23.0 during the session, while it also had its lowest trading level at $22.21.
Ratios:
For a deeper understanding of Centessa Pharmaceuticals plc ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.57 and its Current Ratio is at 10.57. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.39.
On October 28, 2025, Stephens started tracking the stock assigning a Overweight rating and target price of $35.
On September 03, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $31.Wells Fargo initiated its Overweight rating on September 03, 2025, with a $31 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 02 ’26 when Saurabh Saha bought 2,500,000 shares for $24.30 per share.
Accardi Mario Alberto sold 10,000 shares of CNTA for $288,289 on Dec 09 ’25. The President, Orexin Program now owns 178,801 shares after completing the transaction at $28.83 per share. On Dec 09 ’25, another insider, Accardi Mario Alberto, who serves as the Officer of the company, bought 10,000 shares for $29.30 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 3275018240 and an Enterprise Value of 2886365440. For the stock, the TTM Price-to-Sale (P/S) ratio is 200.11 while its Price-to-Book (P/B) ratio in mrq is 9.99. Its current Enterprise Value per Revenue stands at 192.424 whereas that against EBITDA is -13.52.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.57, which has changed by 0.4692005 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $30.58, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is -13.45%, while the 200-Day Moving Average is calculated to be 19.93%.
Shares Statistics:
For the past three months, CNTA has traded an average of 1.59M shares per day and 1321690 over the past ten days. A total of 134.42M shares are outstanding, with a floating share count of 88.33M. Insiders hold about 34.29% of the company’s shares, while institutions hold 60.04% stake in the company. Shares short for CNTA as of 1765756800 were 5662349 with a Short Ratio of 3.57, compared to 1763078400 on 5921306. Therefore, it implies a Short% of Shares Outstanding of 5662349 and a Short% of Float of 4.44.
Earnings Estimates
The market rating for Centessa Pharmaceuticals plc ADR (CNTA) is a result of the insights provided by 9.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.38 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$1.05 and -$1.42 for the fiscal current year, implying an average EPS of -$1.34. EPS for the following year is -$1.65, with 10.0 analysts recommending between -$1.24 and -$2.02.
